Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.

Abstract

Everolimus has clinically relevant antitumor activity in patients with advanced differentiated thyroid cancer. Given the observed disease control rate and the relatively low toxicity profile, further investigation of everolimus in sequential or combination therapy in these patients is warranted.